Karyopharm Therapeut (NQ: KPTI )

14.94 USD -0.38 (-2.48%)

Official Closing Price Updated: 7:59 PM EST, Jan 15, 2021 Add to My Watchlist

Price and Volume

Volume	2,338,400
Open	15.27
Bid (Size)	14.98 (2)
Ask (Size)	15.00 (4)
Prev. Close	15.32
Today's Range	14.86 - 15.39
52wk Range	13.39 - 29.61
Shares Outstanding	60,216,752
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update

January 11, 2021

-- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 --

Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer

January 04, 2021

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in...

Performance

YTD	-11.70%	-11.70%
1 Month	+2.05%	+2.05%
3 Month	-5.44%	-5.44%
6 Month	-21.12%	-21.12%
1 Year	-20.66%	-20.66%

More News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 04, 2021

Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference

January 04, 2021

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

January 03, 2021

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

December 20, 2020

Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

December 18, 2020

Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

December 18, 2020

Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 15, 2020

Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma

December 11, 2020

Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

December 10, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.